Njira Lugogo, CHEST 2021: Tezepelumab for the Treatment of Severe, Uncontrolled Asthma

It was a pleasure to meet with Professor Njira Lugogo (University of Michigan, Ann Arbor, MI, USA) to discuss the findings from the NAVIGATOR study, investigating tezepelumab in adults and adolescents with severe, uncontrolled asthma (NCT03347279).

The abstract ‘TEZEPELUMAB PRODUCES CLINICALLY MEANINGFUL RESPONSES ON PATIENT-REPORTED OUTCOME MEASURES IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA: RESULTS FROM THE PHASE 3 NAVIGATOR STUDY‘ was presented at CHEST 2021, 17-20 October 2021.

Questions

1. What did the NAVIGATOR study teach us about the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma? (0:12)
2. Why was it considered important to perform a pre-specified analysis of patient-reported outcomes? (1:15)
3. What were the findings of this analysis? (2:40)

Disclosures: Njira Lugogo received consulting fees for advisory board participation from Amgen, AstraZeneca, Genentech, GSK, Novartis, Regeneron, Sanofi, and Teva; honoraria for non-speakers bureau presentations from GSK and Astra Zeneca; and travel support from Astra Zeneca; her institution received research support from Amgen, AstraZeneca, Avillion, Gossamer Bio, Genentech, GSK, Regeneron, Sanofi, and Teva.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.

Filmed as a highlight of CHEST 2021 (Virtual).